Newly discovered disease opens for future diabetes treatment

Knowledge of a newly discovered genetic disorder, which means that a person cannot produce the protein TXNIP (thioredoxin interacting protein) in their cells, can open for the development of new diabetes drugs. This is shown in a study from Karolinska Institutet in Sweden published in the journal Diabetes.

With modern techniques more and more previously unknown genetic diseases are being discovered, which can lead to new knowledge about human biology and contribute to the development of new drugs.

Researchers at Karolinska Institutet have recently been using gene sequencing (genome analysis) to investigate a family in which three of the children had excessively high levels of lactate () and simultaneously low levels of the amino acid methionine in the blood, which is an unusual symptom picture. If left untreated, elevated lactate levels can cause , respiratory effects and even fatal outcome, but the children are being given continuous medical treatment and are otherwise well.

"We discovered that the children's symptoms were due to a mutation in the gene that encodes the TXNIP (thioredoxin interacting protein), which had never previously been described in humans. Based on the results in animal models, this protein has been suggested as a possible target for new diabetes drugs, since overexpressing TXNIP in mice induces diabetes, while a lack of TXNIP protects against diabetes," says Anna Wedell, consultant and professor at the Department of Molecular Medicine and Surgery at Karolinska Institutet.

TXNIP is active in the thioredoxin system, which is found in all . The system is of great importance in terms of the ability to make new DNA (genetic material) and to protect cells from reactive radicals. In the current study, the researchers examined cells from the children using more detailed methods and analyses of both the thioredoxin system and sugar metabolism. They also investigated how the mitochondria, which are the cells' energy factories, functioned.

"We found that the TXNIP protein was completely absent from the cells from these patients. The result is that the mitochondria are unable to use pyruvate resulting from the break-down of glucose, as is usually the case when cells use sugar to make energy. Instead, they only produced lactate from pyruvate. However, the were able to use another substance as fuel for the mitochondria—malate. This can explain much of the patients' symptoms, and also shows that a complete absence of TXNIP is compatible with human life," says Elias Arnér, professor at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet, who led the study together with Anna Wedell and Alfredo Giménez-Cassina at the Universidad Autónoma de Madrid.

It has not previously been known what happens in humans if TXNIP is absent. The results of the new study provide important insights into the significance of TXNIP and strengthen the hypothesis for TXNIP being a potential target for drug treatment in diabetes, provided that any high lactate levels as a result of such treatment can be managed.

"Studying patients in whom this protein is entirely absent can give some idea of the potential effects of a drug that inhibits the protein, though more studies are needed because these children do not have ," says Elias Arnér.

The researchers now want to conduct further research in order to understand why the children also have low levels of methionine in their blood, and how the metabolism of methionine might be linked to sugar metabolism.


Explore further

TXNIP blocks autophagic flux, causes alpha-synuclein accumulation

More information: Absence of TXNIP in Human Gives Lactic Acidosis and Low Serum Methionine Linked to Deficient Respiration on Pyruvate. Diabetes doi.org/10.2337/db18-0557
Provided by Karolinska Institutet
Citation: Newly discovered disease opens for future diabetes treatment (2019, February 12) retrieved 19 February 2019 from https://medicalxpress.com/news/2019-02-newly-disease-future-diabetes-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more